Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × talquetamab × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 29 Recurrence 4 Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1 Leukemia, Plasma Cell 1 Infections 1 Immunoglobulin Light-chain Amyloidosis 1 Hematologic Neoplasms 1 Cytokine Release Syndrome 1

Interventions

Lenalidomide 5 Dexamethasone 4 fludarabine phosphate 2 daratumumab 2 Whole-Body Irradiation 2 Cyclophosphamide 2 Calcium Dobesilate 2 talquetamab 1 selinexor 1 ixazomib 1 isatuximab 1 fludarabine 1 Transplantation, Autologous 1 Sirolimus 1 Rituximab 1 Mycophenolic Acid 1 Melphalan 1 Bortezomib 1 Blood Specimen Collection 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06993675 2025-08-29

ROTATE

Yale University

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡